赴高容量中心行食管切除术与生存改善相关
该队列研究纳入2010-2021年美国国家癌症数据库17 970例I-III期食管腺癌患者,比较赴高容量中心(HVC)与本地低容量中心(LVC)行食管切除术的生存差异。结果显示赴HVC组1年死亡风险HR 0.69、5年HR 0.80,III期患者获益更明显,且淋巴结清扫更多、切缘阴性率更高。
要点
- III期患者赴HVC获益显著,I期患者两组结局相当。
- 赴HVC与更多淋巴结清扫及更高切缘阴性率相关。
核心结论
- 赴高容量中心行食管切除术与优于本地低容量中心的1年和5年生存相关,尤其在局部进展期患者中。
研究设计与样本
- 基于2010-2021年美国国家癌症数据库的队列研究,纳入17 970例I-III期食管腺癌患者。
- 赴HVC组为旅行负担前25百分位且就诊于年手术量前25百分位中心者,共2342例(13%)。
- 本地LVC组为旅行负担后25百分位且就诊于年手术量后25百分位中心者,共1969例(11%)。
主要发现
- 以本地LVC为参照,赴HVC与1年生存更优相关(HR 0.69;95%CI 0.58-0.83)。
- 赴HVC与5年生存更优相关(HR 0.80;95%CI 0.70-0.90)。
- III期患者赴HVC与死亡风险降低相关(1年HR 0.72;95%CI 0.60-0.87;5年HR 0.83;95%CI 0.74-0.93),I期患者两组结局相当。
- 赴HVC与更多淋巴结清扫相关(β=5.08个淋巴结;95%CI 3.78-6.37)。
- 赴HVC与切缘阴性切除可能性更高相关(校正OR 1.83;95%CI 1.29-2.60)。
临床怎么用
- 对I-III期食管腺癌拟行食管切除术者,尤其III期患者,可考虑转诊至高容量中心以改善生存。
- 评估时应结合患者旅行负担与中心年手术量,权衡转诊获益与术后连续性照护。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Ongoing efforts have encouraged the regionalization of esophageal adenocarcinoma treatment to high-volume centers (HVCs). Yet such centralization has been linked with increased patient travel burden and reduced postoperative continuity of care. OBJECTIVE: To determine whether traveling to undergo esophagectomy at HVCs is linked with superior overall survival compared with receiving care locally at low-volume centers (LVC). DESIGN, SETTING, AND PARTICIPANTS: This cohort study considered data for all patients diagnosed with stage I through III esophageal adenocarcinoma in the 2010-2021 National Cancer Database. Patients were stratified based on distance traveled to receive care and the annual esophagectomy volume at the treating hospital: the travel-HVC cohort included patients in the top 25th percentile of travel burden who received care at centers in the top volume quartile, and the local-LVC cohort represented those in the bottom 25th percentile of travel burden who were treated at centers in the lowest volume quartile. Data were analyzed from July 2023 to January 2024. MAIN OUTCOMES AND MEASURES: The primary end points were overall survival at 1 year and 5 years. Secondary end points included perioperative outcomes and factors linked with traveling to receive care. RESULTS: Of 17 970 patients, 2342 (13%) comprised the travel-HVC cohort, and 1969 (11%), the local-LVC cohort. The median (IQR) age was 65 (58-71) years; 3748 (87%) were male and 563 (13%) were female. After risk adjustment and with care at local LVCs as the reference, traveling to HVC was associated with superior survival at 1 year (hazard ratio for mortality [HR], 0.69; 95% CI, 0.58-0.83) and 5 years (HR, 0.80; 95% CI, 0.70-0.90). Stratifying by stage, traveling to HVCs was associated with comparable outcomes for stage I disease but reduced mortality for stage III (1-year HR, 0.72; 95% CI, 0.60-0.87; 5-year HR, 0.83; 95% CI, 0.74-0.93). Further, traveling to HVC was associated with greater lymph node harvest (β, 5.08 nodes; 95% CI, 3.78-6.37) and likelihood of margin-negative resection (adjusted odds ratio, 1.83; 95% CI, 1.29-2.60). CONCLUSIONS AND RELEVANCE: Traveling to HVCs for esophagectomy was associated with improved 1-year and 5-year survival compared with receiving care locally at LVCs, particularly among patients with locoregionally advanced disease. Future studies are needed to ascertain barriers to care and develop novel targeted pathways to ensure equitable access to high-volume facilities and high-quality oncologic care.
引用
- Sakowitz S, Bakhtiyar SS, Mallick S, et al. Travel to High-Volume Centers and Survival After Esophagectomy for Cancer. JAMA Surg. 2025. PMID: 39535737. doi:10.1001/jamasurg.2024.5009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。